New trial
Phase 1 trial of atezolizumab PD-L1 mAb combined with CIML natural killer cells in AML.
- Trial ID
- NCT07011004 on ClinicalTrials.gov
- Cancer type
- Acute Myeloid Leukemia
- Stage of research
- Exploratory
- Location
- 7 Locations
- Published in
- New in Oncology - July 3, 2025
This study aims to determine the maximum tolerated dose of cytokine-induced memory-like NK cells with atezolizumab and IL-2 in relapsed/refractory acute myelogenous leukemia. Participants have various genetic AML subtypes lacking standard care options. Memorial Sloan Kettering leads the trial employing standard lymphodepleting chemotherapy to assess safety and preliminary efficacy.
More in acute myeloid leukemia and MDS
-
Trial result · Oct 22, 2026 · NCT03672539
CPX-351 (liposomal daunorubicin/cytarabine) + CD33-targeted gemtuzumab ozogamicin delivers 19% CRc in heavily pretreated R/R AML -
New trial · Oct 15, 2026 · NCT07809906
Phase 1 ORM-1153 CD123-directed degrader-antibody conjugate delivers a GSPT1-degrading payload in hematologic malignancies -
Trial result · Sep 17, 2026 · NCT02159495
CD123 CAR-T Delivers ~27% CR/CRi in Post-alloHCT AML With Manageable CRS/Neurotoxicity -
New trial · Sep 10, 2026 · NCT07581002
Phase 2/3 Pivekimab sunirine CD123-targeted ADC (IGN payload) + venetoclax/azacitidine in AML -
New trial · Sep 10, 2026 · NCT07780565
Phase 1b monzosertib CDC7 kinase inhibitor tests azole–drug interaction dosing in AML/MDS